1. Home
  2. MLYS vs HIFS Comparison

MLYS vs HIFS Comparison

Compare MLYS & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • HIFS
  • Stock Information
  • Founded
  • MLYS 2019
  • HIFS 1834
  • Country
  • MLYS United States
  • HIFS United States
  • Employees
  • MLYS N/A
  • HIFS N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • HIFS Major Banks
  • Sector
  • MLYS Health Care
  • HIFS Finance
  • Exchange
  • MLYS Nasdaq
  • HIFS Nasdaq
  • Market Cap
  • MLYS 893.0M
  • HIFS 485.3M
  • IPO Year
  • MLYS 2023
  • HIFS N/A
  • Fundamental
  • Price
  • MLYS $15.61
  • HIFS $259.31
  • Analyst Decision
  • MLYS Strong Buy
  • HIFS
  • Analyst Count
  • MLYS 3
  • HIFS 0
  • Target Price
  • MLYS $33.00
  • HIFS N/A
  • AVG Volume (30 Days)
  • MLYS 679.3K
  • HIFS 11.3K
  • Earning Date
  • MLYS 05-12-2025
  • HIFS 04-11-2025
  • Dividend Yield
  • MLYS N/A
  • HIFS 0.98%
  • EPS Growth
  • MLYS N/A
  • HIFS 14.93
  • EPS
  • MLYS N/A
  • HIFS 12.96
  • Revenue
  • MLYS N/A
  • HIFS $67,590,000.00
  • Revenue This Year
  • MLYS N/A
  • HIFS N/A
  • Revenue Next Year
  • MLYS N/A
  • HIFS N/A
  • P/E Ratio
  • MLYS N/A
  • HIFS $19.57
  • Revenue Growth
  • MLYS N/A
  • HIFS 12.43
  • 52 Week Low
  • MLYS $8.24
  • HIFS $164.00
  • 52 Week High
  • MLYS $18.38
  • HIFS $300.00
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 60.58
  • HIFS 61.75
  • Support Level
  • MLYS $14.03
  • HIFS $250.58
  • Resistance Level
  • MLYS $15.79
  • HIFS $254.99
  • Average True Range (ATR)
  • MLYS 0.95
  • HIFS 5.51
  • MACD
  • MLYS 0.15
  • HIFS 1.29
  • Stochastic Oscillator
  • MLYS 94.04
  • HIFS 91.29

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About HIFS Hingham Institution for Savings

Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.

Share on Social Networks: